Abstracts tagged "malignancy and systemic sclerosis"

Abstract Number: 3260 • 2015 ACR/ARHP Annual Meeting
Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: A Eustar Multicentre Study
Maria Grazia Lazzaroni¹, Enrico Colombo², Ilaria Cavazzana¹, Oliver Distler³, Rucsandra Dobrota³, Jasmin Eisenring³, Roger Hesselstrand⁴, Lazlo Czirjak⁵, Cecilia Varju⁵, Gabriella Nagy⁵, Vanessa Smith⁶, Paola Caramaschi⁷, Valeria Riccieri⁸, Eric Hachulla⁹, Katarzyna Romanowska-Próchnicka¹⁰, Alexandra Balbir-Gurman¹¹, Emmanuel Chatelus¹², Ana Carolina Araújo¹³, Yannick Allanore¹⁴, Paolo Airò¹⁵ and EUSTAR , ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, University and Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁵University of Pécs Medical Center, Pécs, Hungary, ⁶Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy, ⁸Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, ⁹Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ¹⁰Department of Pathophysiology, Medical University of Warsaw and Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland, ¹¹B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, ¹²Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Serviço de Medicina 2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁴Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹⁵Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, Brescia, Italy
Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: a EUSTAR Multicentre Study Background/Purpose: Several clinical issues…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].